A Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2018
At a glance
- Drugs GEN 1 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 03 May 2017 Status changed from active, no longer recruiting to completed.
- 07 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Feb 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.